Alembic Pharmaceuticals partners with Amlan International to bring innovative poultry health solutions to India's market.
The Nippon India Pharma Fund - Growth has an AUM of 7637.04 crores & has delivered CAGR of 27.43% in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of 1.82%. The minimum ...
The Trump administration's decision to exempt tariffs on Indian pharma imports brings relief to a $9 billion-plus US export market, highlighting India's key role in providing affordable generic ...
The project will be an extension of the CDSCO and NIHFW's ongoing training programmes with drug inspectors from the central ...
The session highlighted existing policy support mechanisms and upcoming opportunities under the PRIP scheme aimed at ...
AI generated image India's pharma sector has emerged as a big winner amid Trump’s tariff woes, as the US has exempted pharmaceuticals from reciprocal tariffs, recognizing the vital role of India ...
The US market accounts for 30% of overall exports for India’s pharma sector. The industry welcomed the decision, saying that it underscores the critical role of cost-effective, life-saving generic ...
US president Donald Trump exempted imports of pharmaceuticals, energy and certain minerals in his “reciprocal tariffs” on Thursday, likely providing reprieve to India’s generic medicines industry.
1. Current NAV: The Current Net Asset Value of the Nippon India Pharma Fund as of Apr 04, 2025 is Rs 109.27 for IDCW option of its Regular plan. 2. Returns: Its trailing returns over different time ...
Dr. Reddy’s Laboratories Ltd., Sun Pharma Ltd. Reciprocal tariffs for more than 60 countries, including India, the European Union, China, Vietnam, among others were announced by Trump.